Table 1.
Current therapeutic approaches for the management of neurodegenerative disorders.
| Neurological Disorder | Drug Class | Mechanism | Drugs |
|---|---|---|---|
| Alzheimer disease | Amyloid-directed antibody | Acts by targeting and removing amyloid-beta plaques | Aducanumab |
| Cholinesterase Inhibitors | Prevent the knockdown of acetylcholine | Donepezil, rivastigmine, galantamine | |
| Glutamate regulators | Antagonize N-methyl-D-aspartate (NMDA) receptor to improve signal-to-noise ratio of glutamatergic transmission | Memantine | |
| Parkinson disease | Dopamine supplements | Replenish the decreased dopamine levels | Levodopa |
| Decarboxylase inhibitors | Prevent peripheral breakdown of levodopa | Carbidopa | |
| Dopamine agonist | Produces dopamine-like effects | Apomorphine hydrochloride, pergolide, pramipexole dihydrochloride, ropinirole hydrochloride, rotigotine | |
| Amyotrophic Lateral Sclerosis | Glutamate-receptor antagonist | Inhibits glutamate receptors | Riluzole |
| Free-radical scavanger | Scavanges free radicals | Edaravone |